Compare · AGL vs BXRX
AGL vs BXRX
Side-by-side comparison of agilon health inc. (AGL) and Baudax Bio Inc. (BXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and BXRX operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- AGL is the larger of the two at $1.59B, about 108.2x BXRX ($14.7M).
- AGL has hit the wire 10 times in the past 4 weeks while BXRX has been quiet.
- AGL has more recent analyst coverage (25 ratings vs 0 for BXRX).
- Company
- agilon health inc.
- Baudax Bio Inc.
- Price
- $99.57+4.38%
- $0.18+5.03%
- Market cap
- $1.59B
- $14.7M
- 1M return
- +84.41%
- -
- 1Y return
- +74.29%
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 0
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Baudax Bio Inc.
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Latest AGL
- Chief Legal Officer Zamore Denise covered exercise/tax liability with 485 shares, decreasing direct ownership by 0.73% to 66,112 units (SEC Form 4) (tax liability)
- Director Wulf John William was granted 2,133 shares, increasing direct ownership by 15% to 16,765 units (SEC Form 4)
- Director Williams Ronald A was granted 2,133 shares, increasing direct ownership by 1% to 149,141 units (SEC Form 4)
- Director Mcloughlin Karen was granted 2,133 shares, increasing direct ownership by 35% to 8,207 units (SEC Form 4)
- Director Mckenzie Diana was granted 2,133 shares, increasing direct ownership by 39% to 7,633 units (SEC Form 4)
- Director Mansukani Sharad was granted 2,133 shares, increasing direct ownership by 4% to 56,242 units (SEC Form 4)
- Director Battaglia Silvana was granted 2,133 shares, increasing direct ownership by 37% to 7,926 units (SEC Form 4)
- agilon health inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 8 shares, decreasing direct ownership by 0.06% to 14,169 units (SEC Form 4) (for withholding tax)
- agilon health upgraded by Barclays with a new price target
Latest BXRX
- SEC Form 8-K filed by Baudax Bio Inc.
- SEC Form 25-NSE filed by Baudax Bio Inc.
- SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
- SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
- Baudax Bio Inc. filed SEC Form 8-K: Other Events
- CORRECTION: BioCryst Pharmaceuticals Ticker is "BCRX
- BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
- SEC Form 424B3 filed by Baudax Bio Inc.
- SEC Form 10-Q filed by Baudax Bio Inc.
- SEC Form NT 10-Q filed by Baudax Bio Inc.